BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
7.67 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | BioCryst Pharmaceuticals, Inc. |
Symbool | BCRX |
Munteenheid | USD |
Prijs | 7.67 |
Beurswaarde | 1,586,815,620 |
Dividendpercentage | 0% |
52-weken bereik | 4.03 - 8.88 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jon P. Stonehouse |
Website | https://www.biocryst.com |
An error occurred while fetching data.
Over BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)